EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Visual Prognosis of Patients Following Lens-Sparing Vitrectomy for Stage 4A Retinopathy of Prematurity

Chiharu Iwahashi iD, Tomoki Kurihara, Kazuki Kuniyoshi, Shunji Kusaka iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24032416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Chiharu Iwahashi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Kindai University, Osakasayama 589-8511, Japan. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Myopia, Infant, Newborn, Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: a grant-in-aid from the Ministry of Education, Culture, Sport, Science and Technology, Japan, Ministry of Education, Culture, Sport, Science and Technology, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the long-term visual outcomes of patients in whom at least one eye underwent successful lens-sparing vitrectomy (LSV) for stage 4A retinopathy of prematurity (ROP). A retrospective chart review was conducted using the data of 61 eyes of 42 patients with a minimum 4-year follow-up after successful LSV, with or without anti-vascular endothelial growth factor (VEGF) therapy, and whose best-corrected visual acuity (BCVA) was measurable using Landolt rings at the final visit. The mean age at the final follow-up was 10.1 ± 3.3 years. Before LSV, all eyes underwent laser ablation therapy. Twenty eyes (32.8%) with high vascular activity received anti-VEGF therapy before LSV. The mean decimal BCVA at the final follow-up was 0.23 ± 0.26 (range: hand motion to 1.2). Twenty-three eyes (54.1%) had a decimal BCVA of ≥0.4. Among 49 phakic eyes at the final examination, the mean refractive error was −10.1 ± 5.0 D, with 37 eyes (75.5%) having high myopia (>−6.0 D). No significant differences were observed in terms of decimal BCVA and refractive errors between eyes with and without anti-VEGF therapy. Approximately half of the patients had a decimal BCVA of ≥0.4, despite myopic refraction after successful LSV for stage 4A ROP. LSV for stage 4A ROP seemed to be associated with good visual function, despite myopic refraction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinopathy of PrematurityMyopiaInfant, Newborn, DiseasesInfant, NewbornHumansChildAdolescentVitrectomyRetrospective StudiesVisual AcuityTreatment OutcomeFollow-Up StudiesGestational Age

Stichwörter der Autor:innen

anti-vascular endothelial growth factorlaserlens-sparing vitrectomymyopiarefractive errorretinopathy of prematurityvisual acuityvitrectomy

Autor:innen und Institutionen

  • Department of Ophthalmology, Faculty of Medicine, Kindai University, Osakasayama 589-8511, Japan.

ORCID-Profile: Chiharu Iwahashi, Shunji Kusaka

Förderung

  • a grant-in-aid from the Ministry of Education, Culture, Sport, Science and Technology, Japan
  • Ministry of Education, Culture, Sport, Science and Technology, Japan

Zitieren

APA

Iwahashi, C., Kurihara, T., Kuniyoshi, K., & Kusaka, S. (2023). Long-Term Visual Prognosis of Patients Following Lens-Sparing Vitrectomy for Stage 4A Retinopathy of Prematurity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032416

Vancouver

Iwahashi C, Kurihara T, Kuniyoshi K, Kusaka S. Long-Term Visual Prognosis of Patients Following Lens-Sparing Vitrectomy for Stage 4A Retinopathy of Prematurity. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032416

BibTeX
@article{Iwahashi2023,
  author = {Iwahashi, Chiharu and Kurihara, Tomoki and Kuniyoshi, Kazuki and Kusaka, Shunji},
  title = {Long-Term Visual Prognosis of Patients Following Lens-Sparing Vitrectomy for Stage 4A Retinopathy of Prematurity},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24032416}
}
Kostenlos starten →